Viatris Launches Inpefa® (Sotagliflozin) for the Treatment of Heart Failure in the UAE

In January 22026, Viatris Inc., a global healthcare organization, announced the launch of Inpefa® (sotagliflozin) in the UAE, marking the first market within the Viatris territories to commercialize this innovative treatment. Additional launches are anticipated in multiple countries over the forthcoming years, aligning with Viatris' strategy to enhance access to the treatment in key markets beyond the United States and Europe.

Inpefa is the first and only dual SGLT1/2 inhibitor approved for the management of heart failure. The FDA approved it for use in both the U.S. and the UAE, recognizing its efficacy in reducing the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visits among adults suffering from heart failure or type 2 diabetes mellitus, chronic kidney disease, and other cardiovascular risk factors.

The introduction of Inpefa in the UAE represents a significant milestone in the organization's mission to deliver innovative medications to patients globally, as stated by Corinne Le Goff, Chief Commercial Officer of Viatris. Philippe Martin remarked, " Our success in broadening the global reach of Inpefa is indicative of our expanding innovative pipeline, which includes several late-stage programs progressing at a robust pace. Regulatory filings have been submitted in several countries, including Canada, Australia, and Mexico, with plans to further broaden global submissions over the coming years.

The approval of Inpefa is based on two pivotal Phase 3 trials, namely SOLOIST-WHF and SCORED, enrolling more than 11,800 patients worldwide and significantly lowering the risk of major cardiovascular events in high-risk populations. In SOLOIST-WHF, Inpefa lowered the composite risk of heart failure hospitalization, urgent visits, and cardiovascular death by 33% versus placebo in patients recently hospitalized for worsening heart failure, with benefits rising up to 51% when initiated before discharge and evident within 30 days post-discharge.

Impact on Cardiovascular Drugs Industry

The global cardiovascular drugs market size is calculated at USD 155.96 billion in 2025 and is expected to grow from USD 162.02 billion in 2026 to approximately USD 221.20 billion by 2035, expanding at a CAGR of 3.56% from 2026 to 2035.

According to precedence research, the growing number of patients suffering from cardiovascular diseases has boosted the market to record considerable growth. The rising prevalence of cardiac arrest and cardiac arrhythmias has boosted the demand for cardiovascular drugs in society.

Heart failure is the prominent cause of hospitalization in the world, affecting more than 64 million people globally. It is anticipated that one in every five people will develop heart failure during their lifetime. After hospital discharge, both mortality and readmission rates remain substantial worldwide, and as such, there is a consistent need for new treatments to help address this burden. This launch also builds upon our robust legacy in cardiovascular diseases, reinforcing our commitment to expand the impact of Inpefa to help address the needs of patients around the globe.

Impact on the SGLT-2 Inhibitors Industry

The global SGLT-2 inhibitors market size is calculated at USD 18.18 billion in 2025 and is expected to grow from USD 19.31 billion in 2026 to approximately USD 33.11 billion by 2035, expanding at a CAGR of 6.18% from 2026 to 2035.

According to precedence research, academic institutions increasingly complement pharmaceutical innovation, with clinical data demonstrating reductions in hospitalization and mortality, thereby growing the cardiometabolic therapy pipeline. The growing body of clinical evidence supporting a reduced risk of heart failure and the progression of chronic kidney disease has led to increased clinical utilization of certain medications. Beyond controlling blood sugar levels in type 2 diabetes, these medications are increasingly being used to address cardiovascular diseases (such as heart failure), chronic kidney disease, obesity, and other metabolic risk factors.

Sotagliflozin is an oral medication that inhibits two proteins involved in glucose regulation, known as sodium glucose cotransporter types 2 and 1. It has been studied in various patient populations, including those with heart failure, diabetes, and chronic kidney disease, involving approximately 20,000 participants in clinical studies. In May 2023, the U.S. Food and Drug Administration approved sotagliflozin to reduce the risk of cardiovascular death, hospitalization due to heart failure, and urgent heart failure visits in adults with heart failure or type 2 diabetes mellitus alongside chronic kidney disease.

About Company

Viatris Inc. is a global healthcare company dedicated to empowering individuals worldwide to live healthier at every stage of life. Formed in November 2020 through the merger of Mylan and Upjohn, the company believes that better access to medicines leads to better health outcomes. Viatris leverages its top-tier manufacturing and scientific expertise, as well as proven commercial capabilities, to provide quality medicines to patients when and where they need them.

From cardiovascular health to oncology, Viatris offers effective treatment options across more than 10 major therapeutic areas, addressing a wide range of noncommunicable and infectious diseases. Additionally, Viatris provides support services such as diagnostic clinics, educational seminars, and digital tools to help patients manage their health effectively.